dsip vs selank

updated October 27, 2026

dsip (tier C) vs selank (tier B): what each is, why each got its grade, half-life and source counts side by side.

dsip · tier C

isolated 1977 as a sleep peptide. 50 years of trials, no clinical breakthrough. community uses it anyway.

tier rationale

C-tier because DSIP has had nearly 50 years of on-again off-again clinical research without producing convergent evidence of efficacy. Some positive trials exist, particularly for sleep and alcohol withdrawal, but the field never reached consensus and the compound never achieved drug-approval status anywhere. The mechanism is unclear: no confirmed receptor, no clean pathway. Not D-tier because the trial literature is real and includes legitimate positive findings, the peptide is well-characterized biochemically, and community responders do seem to exist. Not B-tier because the gap between 'occasionally shown to help' and 'consistently shown to help' is exactly what separates C from B.

selank · tier B

russian anti-anxiety peptide. head-to-head benzodiazepine trials, lighter sedation signal, thin Western long-term data.

tier rationale

B-tier because the evidence is real: Russian regulatory approval, comparison trials against established benzodiazepines, multi-pathway mechanism documentation. But it's structured outside Western clinical recognition. The absence of FDA or EMA evaluation means most Western clinicians have no framework for considering it, despite strong evidence by the standards that produced its original approval. If Western regulatory attention ever reaches Selank the way it's reaching Semax in 2026, tier placement would likely move up.

at a glance

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.